6-Methyl-4-[[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]amino]chromen-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-Methyl-4-[[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]amino]chromen-2-one
• 化学式: C₂₃H₂₃F₃N₂O₃
• 分子量: 432.4
• InChiKey: MFIDMTCYKKRZAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Antagonists of melanin concentrating hormone receptor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040106645A1

  公开（公告）日：2004-06-03

  This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: 1 where m is zero or one, n is zero to two, Y is oxygen or —N(R 9 )—, R 1 , R 2 , R 3 , R 4 , R 5 , R 9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R 1 and R 2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

  这项发明提供了一些与黑色素浓集激素受体-1 (MCH-R1) 相对抗的化合物。这些化合物由公式 I 表示：其中 m 为零或一，n 为零至二，Y 为氧或 —N(R9)—，R1、R2、R3、R4、R5、R9 和环 A 在说明书中有定义。偏好使用 R1 和 R2 结合形成融合苯环的香豆素和喹啉类化合物。该发明还提供了公式 VI 的化合物，其中香豆素基团被喹嗪酮环替换。这些化合物可用于治疗与 MCH-R1 相关的疾病，特别是超重症，包括肥胖症。
• ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR
  申请人：ABBOTT LABORATORIES

  公开号：EP1534703A2

  公开（公告）日：2005-06-01
• US6921821B2
  申请人：——

  公开号：US6921821B2

  公开（公告）日：2005-07-26
• [EN] ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'HORMONE DE MELANO-CONCENTRATION
  申请人：MILLENNIUM PHARM INC

  公开号：WO2003106452A2

  公开（公告）日：2003-12-24

  This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R9)-, R1, R2, R3, R4, R5, R9, and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.